Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 2

Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne

NCT00706433 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to determine and compare the safety and efficacy of multiple broad area photodynamic therapy treatments with aminolevulinic acid (ALA-PDT) and vehicle (VEH-PDT) in subjects with moderate to severe facial acne vulgaris.

Conditions Studied

Interventions

  • DRUG aminolevulinic acid HCL (ALA)
  • OTHER Vehicle (VEH)

Study Locations (14)

Texas

  • Derm Research Inc — Austin
  • Baylor Research Institute — Dallas

Arkansas

  • Burke Pharmaceutical Research — Hot Springs

California

  • Therapeutics Clinical Research — San Diego

Colorado

  • Cherry Creek Research, Inc. — Denver

Florida

  • Kenneth R. Beer, M.D. P.A. — West Palm Beach

Georgia

  • Gwinnett Clinical Research Center, Inc. — Snellville

Indiana

  • Laser and Skin Surger Center of Indiana — Carmel

Kentucky

  • Derm Research PLLC — Louisville

Trial Details

FieldValue
Enrollment Target 266 participants
Start Date 2007-03
Est. Completion 2008-07
Phase Phase 2

Sponsor

DUSA Pharmaceuticals

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00706433

The ClinicalTrials.gov registry entry for NCT00706433 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 266 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DUSA Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions — of which aminolevulinic acid HCL (ALA) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00706433 reports 14 study locations spanning 13 distinct geographic areas — top geographies include Texas, Arkansas, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00706433 about?

NCT00706433 is a clinical study titled "Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne". The purpose of this study is to determine and compare the safety and efficacy of multiple broad area photodynamic therapy treatments with aminolevulinic acid (ALA-PDT) and vehicle (VEH-PDT) in subjects with moderate to severe facial acne vulgaris.

What is the current status of trial NCT00706433?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 266 participants. The study started on 2007-03. Estimated completion is 2008-07.

What conditions does trial NCT00706433 study?

This clinical trial studies the following conditions: Acne Vulgaris. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00706433?

The interventions under investigation include: aminolevulinic acid HCL (ALA) (DRUG), Vehicle (VEH) (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00706433?

This trial is sponsored by DUSA Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00706433 being conducted?

This trial has 14 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial